251 related articles for article (PubMed ID: 15950483)
1. Thyrotropin receptor autoantibodies in Graves' disease.
Schott M; Scherbaum WA; Morgenthaler NG
Trends Endocrinol Metab; 2005 Jul; 16(5):243-8. PubMed ID: 15950483
[TBL] [Abstract][Full Text] [Related]
2. Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay.
Morgenthaler NG; Hodak K; Seissler J; Steinbrenner H; Pampel I; Gupta M; McGregor AM; Scherbaum WA; Banga JP
Thyroid; 1999 May; 9(5):466-75. PubMed ID: 10365678
[TBL] [Abstract][Full Text] [Related]
3. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and discrimination of autoimmune Graves' disease and Hashimoto's disease using thyroid-stimulating hormone receptor-containing recombinant proteoliposomes.
Fukushima H; Matsuo H; Imamura K; Morino K; Okumura K; Tsumoto K; Yoshimura T
J Biosci Bioeng; 2009 Dec; 108(6):551-6. PubMed ID: 19914592
[TBL] [Abstract][Full Text] [Related]
5. Immunoprecipitation analysis of pathological autoantibodies in Graves' patients' sera using biotinylated human thyrotropin receptor labeled with 125I-neutravidiny.
Minich WB; Weymayer JD; Loos U
Exp Clin Endocrinol Diabetes; 1999; 107(8):555-60. PubMed ID: 10612487
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in laboratory tests for autoantibodies to thyrotropin receptor protein in Graves' disease.
Gupta MK
Clin Lab Med; 1988 Jun; 8(2):303-23. PubMed ID: 3284698
[TBL] [Abstract][Full Text] [Related]
7. Techniques to quantify TSH receptor antibodies.
Ajjan RA; Weetman AP
Nat Clin Pract Endocrinol Metab; 2008 Aug; 4(8):461-8. PubMed ID: 18574503
[TBL] [Abstract][Full Text] [Related]
8. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Fiore E; Bucci I; Chamblin T; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1106-15. PubMed ID: 22496495
[TBL] [Abstract][Full Text] [Related]
9. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance.
Ando T; Latif R; Davies TF
Best Pract Res Clin Endocrinol Metab; 2005 Mar; 19(1):33-52. PubMed ID: 15826921
[TBL] [Abstract][Full Text] [Related]
10. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
Wallaschofski H; Kuwert T; Lohmann T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
[TBL] [Abstract][Full Text] [Related]
11. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
12. On specificity of 2nd generation TSH receptor autoantibody measurements.
Zöphel K; Grüning T; Roggenbuck D; Wunderlich G; Kotzerke J
Clin Lab; 2008; 54(7-8):243-9. PubMed ID: 18942492
[TBL] [Abstract][Full Text] [Related]
13. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus encoding the thyrotropin receptor A-subunit improves the efficacy of dendritic cell-induced Graves' hyperthyroidism in mice.
Mizutori Y; Saitoh O; Eguchi K; Nagayama Y
J Autoimmun; 2006 Feb; 26(1):32-6. PubMed ID: 16242303
[TBL] [Abstract][Full Text] [Related]
15. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
[TBL] [Abstract][Full Text] [Related]
16. Evidence that TSH Receptor A-Subunit Multimers, Not Monomers, Drive Antibody Affinity Maturation in Graves' Disease.
Rapoport B; Aliesky HA; Chen CR; McLachlan SM
J Clin Endocrinol Metab; 2015 Jun; 100(6):E871-5. PubMed ID: 25856215
[TBL] [Abstract][Full Text] [Related]
17. Epitopes for thyroid stimulating and blocking autoantibodies on the extracellular domain of the human thyrotropin receptor.
Tahara K; Ishikawa N; Yamamoto K; Hirai A; Ito K; Tamura Y; Yoshida S; Saito Y; Kohn LD
Thyroid; 1997 Dec; 7(6):867-77. PubMed ID: 9459630
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune thyrotoxicosis: diagnostic challenges.
Ponto KA; Kahaly GJ
Am J Med; 2012 Sep; 125(9):S1. PubMed ID: 22938935
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of experimental Graves' disease by intranasal administration of a T cell epitope of the thyrotropin receptor.
Arima T; Shimojo N; Yamaguchi K; Tomiita M; Kohn LD; Kohno Y
Clin Immunol; 2008 Apr; 127(1):7-13. PubMed ID: 18234558
[TBL] [Abstract][Full Text] [Related]
20. Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies.
Latrofa F; Chazenbalk GD; Pichurin P; Chen CR; McLachlan SM; Rapoport B
J Clin Endocrinol Metab; 2004 Sep; 89(9):4734-45. PubMed ID: 15356088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
